303 related articles for article (PubMed ID: 23558900)
1. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
Lips EH; Mulder L; Oonk A; van der Kolk LE; Hogervorst FB; Imholz AL; Wesseling J; Rodenhuis S; Nederlof PM
Br J Cancer; 2013 May; 108(10):2172-7. PubMed ID: 23558900
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
3. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
[TBL] [Abstract][Full Text] [Related]
4. Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Oonk AMM; van Rijn C; Smits MM; Mulder L; Laddach N; Savola SP; Wesseling J; Rodenhuis S; Imholz ALT; Lips EH
Ann Oncol; 2012 Sep; 23(9):2301-2305. PubMed ID: 22357256
[TBL] [Abstract][Full Text] [Related]
5. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.
Pern F; Bogdanova N; Schürmann P; Lin M; Ay A; Länger F; Hillemanns P; Christiansen H; Park-Simon TW; Dörk T
PLoS One; 2012; 7(10):e47993. PubMed ID: 23110154
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
[TBL] [Abstract][Full Text] [Related]
9. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC
Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055
[TBL] [Abstract][Full Text] [Related]
10. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
[TBL] [Abstract][Full Text] [Related]
11. Triple negative tumours: a critical review.
Reis-Filho JS; Tutt AN
Histopathology; 2008 Jan; 52(1):108-18. PubMed ID: 18171422
[TBL] [Abstract][Full Text] [Related]
12. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
13. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
14. Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness.
Andersen LVB; Larsen MJ; Davies H; Degasperi A; Nielsen HR; Jensen LA; Kroeldrup L; Gerdes AM; Lænkholm AV; Kruse TA; Nik-Zainal S; Thomassen M
Breast Cancer Res; 2023 Jun; 25(1):69. PubMed ID: 37316882
[TBL] [Abstract][Full Text] [Related]
15. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
18. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Eerola H; Heikkilä P; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2005; 7(4):R465-9. PubMed ID: 15987451
[TBL] [Abstract][Full Text] [Related]
19. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
20.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
